• Policy
• Billions of won in losses if applied retroactively
• by Lee, Tak-Sun Jul 22, 2022 05:53am

• Policy
• Negotiations for Pfizer Lorviqua have not been completed
• by Lee, Tak-Sun Jul 22, 2022 05:52am

• Policy
• “Pharma companies cannot conduct online product briefings"
• by Kim, Jung-Ju Jul 21, 2022 06:04am

• Policy
• Companies receive mixed reimb results in urothelial cancer
• by Lee, Tak-Sun Jul 20, 2022 05:49am

• Policy
• The age group for SKYCovione was expanded
• by Lee, Jeong-Hwan Jul 20, 2022 05:49am

• Policy
• Lipilouzet, which is more expensive than Atozet
• by Lee, Tak-Sun Jul 20, 2022 05:49am

• Policy
• To halve the death rate from COVID-19
• by Lee, Jeong-Hwan Jul 18, 2022 06:06am

• Policy
• Abbott has filed a suspension of execution with the court
• by Kim, Jung-Ju Jul 18, 2022 06:06am

• Policy
• Samsung reigns over Avastin biosimilar market in Korea
• by Lee, Tak-Sun Jul 14, 2022 05:54am

• Policy
• No social distancing obligations are introduced
• by Lee, Jeong-Hwan Jul 14, 2022 05:54am